Asarina Pharma (Buy, TP: SEK61.00) - Positive outcome in phase IIb likely
There is a significant unmet need in the treatment of premenstrual dysphoric disorder (PMDD) and treatment options leave much to be desired, with many women not responding to or discontinuing treatment due to side effects. Asarina Pharma’s phase IIa study provided several lessons, which have been addressed in the ongoing phase IIb trial. After reviewing the data from the phase IIb study to date, we believe there are several factors that imply a positive outcome. As a result, we have raised our LOA to 30% (19.6%), and in turn our target price to SEK61 (44). We reiterate our BUY.
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.